In vitro biologic efficacy of sunitinib drugeluting beads on human colorectal and hepatocellular carcinoma-A pilot study

Steven Lahti, Johannes M. Ludwig, Minzhi Xing, Lingyi Sun, Dexing Zeng, Hyun S. Kim

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Purpose Sunitinib drug eluting beads (DEB) are a novel anti-angiogenic bead preparation for use in transarterial chemoembolization. However, systematic studies of sunitinib DEB's effect on cancer cells have not been reported. Herein, we assess their direct biologic efficacy against carcinoma cell lines and correlate cell viability with drug release in vitro. Materials and methods Sunitinib-HCl (10mg/mL) in Milli-Q water was mixed with LC Bead® 300-500μm (Biocompatibles UK Ltd.). Loading and release were assessed by measurement of drug UV absorbance using UV-visible spectrophotometer. Viability of human colorectal cancer (CRC, HCT116 and HT29) and hepatocellular carcinoma (HCC, HepG2) cells upon exposure to sunitinib DEB was measured using a bioluminescent assay. Drug concentration during exposure was quantified using HPLC. Results When added to cultured HepG2 cells, sunitinib DEB rapidly inhibited viability with a significant decrease observed within 1 hour of incubation. Viability of HCT116 and HT29 cells decreased relatively slower, with significant reductions observed after 8 and 24 hours, respectively. After 24 hours there was nearly complete inhibition of all three cell lines. There was no difference in viability observed between cells treated with 5 μl, 10 μL, or 20 μL of sunitinib DEB. HPLC analysis of the cell culture supernatant demonstrated saturation of the cell medium within approximately 4 hours for each amount added, with sunitinib achieving a final concentration of 17.61 μM (SE ±1.01). Conclusions Sunitinib can be efficiently loaded to and released from LC beads, and the resulting sunitinib DEB demonstrate strong in vitro inhibition of human CRC and HCC cells.

Original languageEnglish (US)
Article numbere0174539
JournalPloS one
Volume12
Issue number4
DOIs
StatePublished - Apr 1 2017
Externally publishedYes

Fingerprint

hepatoma
colorectal neoplasms
Hepatocellular Carcinoma
Colorectal Neoplasms
drugs
Pharmaceutical Preparations
viability
Cells
Hep G2 Cells
cells
cell lines
High Pressure Liquid Chromatography
Luminescent Measurements
HCT116 Cells
sunitinib
In Vitro Techniques
Cell Line
HT29 Cells
spectrophotometers
Spectrophotometers

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Agricultural and Biological Sciences(all)

Cite this

In vitro biologic efficacy of sunitinib drugeluting beads on human colorectal and hepatocellular carcinoma-A pilot study. / Lahti, Steven; Ludwig, Johannes M.; Xing, Minzhi; Sun, Lingyi; Zeng, Dexing; Kim, Hyun S.

In: PloS one, Vol. 12, No. 4, e0174539, 01.04.2017.

Research output: Contribution to journalArticle

Lahti, Steven ; Ludwig, Johannes M. ; Xing, Minzhi ; Sun, Lingyi ; Zeng, Dexing ; Kim, Hyun S. / In vitro biologic efficacy of sunitinib drugeluting beads on human colorectal and hepatocellular carcinoma-A pilot study. In: PloS one. 2017 ; Vol. 12, No. 4.
@article{1acbe3f1e09a4118bf3b258963abcddb,
title = "In vitro biologic efficacy of sunitinib drugeluting beads on human colorectal and hepatocellular carcinoma-A pilot study",
abstract = "Purpose Sunitinib drug eluting beads (DEB) are a novel anti-angiogenic bead preparation for use in transarterial chemoembolization. However, systematic studies of sunitinib DEB's effect on cancer cells have not been reported. Herein, we assess their direct biologic efficacy against carcinoma cell lines and correlate cell viability with drug release in vitro. Materials and methods Sunitinib-HCl (10mg/mL) in Milli-Q water was mixed with LC Bead{\circledR} 300-500μm (Biocompatibles UK Ltd.). Loading and release were assessed by measurement of drug UV absorbance using UV-visible spectrophotometer. Viability of human colorectal cancer (CRC, HCT116 and HT29) and hepatocellular carcinoma (HCC, HepG2) cells upon exposure to sunitinib DEB was measured using a bioluminescent assay. Drug concentration during exposure was quantified using HPLC. Results When added to cultured HepG2 cells, sunitinib DEB rapidly inhibited viability with a significant decrease observed within 1 hour of incubation. Viability of HCT116 and HT29 cells decreased relatively slower, with significant reductions observed after 8 and 24 hours, respectively. After 24 hours there was nearly complete inhibition of all three cell lines. There was no difference in viability observed between cells treated with 5 μl, 10 μL, or 20 μL of sunitinib DEB. HPLC analysis of the cell culture supernatant demonstrated saturation of the cell medium within approximately 4 hours for each amount added, with sunitinib achieving a final concentration of 17.61 μM (SE ±1.01). Conclusions Sunitinib can be efficiently loaded to and released from LC beads, and the resulting sunitinib DEB demonstrate strong in vitro inhibition of human CRC and HCC cells.",
author = "Steven Lahti and Ludwig, {Johannes M.} and Minzhi Xing and Lingyi Sun and Dexing Zeng and Kim, {Hyun S.}",
year = "2017",
month = "4",
day = "1",
doi = "10.1371/journal.pone.0174539",
language = "English (US)",
volume = "12",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "4",

}

TY - JOUR

T1 - In vitro biologic efficacy of sunitinib drugeluting beads on human colorectal and hepatocellular carcinoma-A pilot study

AU - Lahti, Steven

AU - Ludwig, Johannes M.

AU - Xing, Minzhi

AU - Sun, Lingyi

AU - Zeng, Dexing

AU - Kim, Hyun S.

PY - 2017/4/1

Y1 - 2017/4/1

N2 - Purpose Sunitinib drug eluting beads (DEB) are a novel anti-angiogenic bead preparation for use in transarterial chemoembolization. However, systematic studies of sunitinib DEB's effect on cancer cells have not been reported. Herein, we assess their direct biologic efficacy against carcinoma cell lines and correlate cell viability with drug release in vitro. Materials and methods Sunitinib-HCl (10mg/mL) in Milli-Q water was mixed with LC Bead® 300-500μm (Biocompatibles UK Ltd.). Loading and release were assessed by measurement of drug UV absorbance using UV-visible spectrophotometer. Viability of human colorectal cancer (CRC, HCT116 and HT29) and hepatocellular carcinoma (HCC, HepG2) cells upon exposure to sunitinib DEB was measured using a bioluminescent assay. Drug concentration during exposure was quantified using HPLC. Results When added to cultured HepG2 cells, sunitinib DEB rapidly inhibited viability with a significant decrease observed within 1 hour of incubation. Viability of HCT116 and HT29 cells decreased relatively slower, with significant reductions observed after 8 and 24 hours, respectively. After 24 hours there was nearly complete inhibition of all three cell lines. There was no difference in viability observed between cells treated with 5 μl, 10 μL, or 20 μL of sunitinib DEB. HPLC analysis of the cell culture supernatant demonstrated saturation of the cell medium within approximately 4 hours for each amount added, with sunitinib achieving a final concentration of 17.61 μM (SE ±1.01). Conclusions Sunitinib can be efficiently loaded to and released from LC beads, and the resulting sunitinib DEB demonstrate strong in vitro inhibition of human CRC and HCC cells.

AB - Purpose Sunitinib drug eluting beads (DEB) are a novel anti-angiogenic bead preparation for use in transarterial chemoembolization. However, systematic studies of sunitinib DEB's effect on cancer cells have not been reported. Herein, we assess their direct biologic efficacy against carcinoma cell lines and correlate cell viability with drug release in vitro. Materials and methods Sunitinib-HCl (10mg/mL) in Milli-Q water was mixed with LC Bead® 300-500μm (Biocompatibles UK Ltd.). Loading and release were assessed by measurement of drug UV absorbance using UV-visible spectrophotometer. Viability of human colorectal cancer (CRC, HCT116 and HT29) and hepatocellular carcinoma (HCC, HepG2) cells upon exposure to sunitinib DEB was measured using a bioluminescent assay. Drug concentration during exposure was quantified using HPLC. Results When added to cultured HepG2 cells, sunitinib DEB rapidly inhibited viability with a significant decrease observed within 1 hour of incubation. Viability of HCT116 and HT29 cells decreased relatively slower, with significant reductions observed after 8 and 24 hours, respectively. After 24 hours there was nearly complete inhibition of all three cell lines. There was no difference in viability observed between cells treated with 5 μl, 10 μL, or 20 μL of sunitinib DEB. HPLC analysis of the cell culture supernatant demonstrated saturation of the cell medium within approximately 4 hours for each amount added, with sunitinib achieving a final concentration of 17.61 μM (SE ±1.01). Conclusions Sunitinib can be efficiently loaded to and released from LC beads, and the resulting sunitinib DEB demonstrate strong in vitro inhibition of human CRC and HCC cells.

UR - http://www.scopus.com/inward/record.url?scp=85017180615&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85017180615&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0174539

DO - 10.1371/journal.pone.0174539

M3 - Article

C2 - 28384190

AN - SCOPUS:85017180615

VL - 12

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 4

M1 - e0174539

ER -